Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

Cancer History Project Conversation with The Cancer Letter

Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities

Soon after he was diagnosed with a dedifferentiated liposarcoma, C. Norman Coleman reached out to The Cancer Letter and the Cancer History Project to initiate a series of interviews about his life and career.

March 22, 2024

Vol.50 No.12

By Otis W. Brawley, Alexandria Carolan and Paul Goldberg

Guest Editorial

The global health contributions of Norm Coleman

We had the privilege of working with Norm Coleman in the International Cancer Expert Corps (ICEC), the NGO he founded in 2013 and where he served as the Senior Scientific Advisor (an approved outside activity from his work at the NCI).

March 22, 2024

Vol.50 No.12

By Nina Wendling and Donna M. O’Brien

An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs

A cruel reminder crept in alongside the joy that overcame Shauna Erickson-Abou Zahr and Abdallah Abou Zahr at the birth of their daughter, Nadia Carmel, on Jan. 11.

February 23, 2024

Vol.50 No.08

By Alexandria Carolan

Clinical Roundup

Experimental drug combination shows promise against hard-to-treat peripheral nerve sheath tumors

Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery.

December 01, 2023

Vol.49 No.44

Funding Opportunities

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

MIB Agents, a pediatric osteosarcoma nonprofit, is accepting applications for its annual OutSmarting Osteosarcoma research grant program. This program was established in 2017 and is awarded to projects focused on moving research forward for osteosarcoma patients.

October 27, 2023

Vol.49 No.40

In Brief

Seven scientists receive $600,000 in grants for osteosarcoma research

Seven scientists will be awarded $600,000 in grants dedicated to osteosarcoma research from MIB Agents, a pediatric osteosarcoma nonprofit. The scientists will be presented their grants at the MIB Agents’ FACTOR Conference in Atlanta, Georgia, this June.

June 16, 2023

Vol.49 No.24

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities

The global health contributions of Norm Coleman

An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs

Experimental drug combination shows promise against hard-to-treat peripheral nerve sheath tumors

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

Seven scientists receive $600,000 in grants for osteosarcoma research

Renew today!

Subscriber content

Login

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities

The global health contributions of Norm Coleman

An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs

Experimental drug combination shows promise against hard-to-treat peripheral nerve sheath tumors

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

Seven scientists receive $600,000 in grants for osteosarcoma research

Login

An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs